Literature DB >> 32435791

Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.

Jianghong Fan1, Xinyuan Zhang1, Jiang Liu1, Yuching Yang1, Nan Zheng1, Qi Liu2, Kimberly Bergman2, Kellie Reynolds3, Shiew-Mei Huang2, Hao Zhu1, Yaning Wang1.   

Abstract

Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antiviral activity; hydroxychloroquine

Mesh：

Substances：

Year:  2020        PMID： 32435791      PMCID： PMC7314136          DOI： 10.1093/cid/ciaa623

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  34 in total

1.  Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.

Authors:  E Leegwater; D J A R Moes; L B E Bosma; T H Ottens; I M van der Meer; C van Nieuwkoop; E B Wilms
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

2.  Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.

Authors:  James M Gallo
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

3.  It is time to drop hydroxychloroquine from our COVID-19 armamentarium.

Authors:  Tarek Kashour; Imad M Tleyjeh
Journal:  Med Hypotheses       Date:  2020-08-17       Impact factor: 1.538

4.  Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2.

Authors:  Nazim Uddin Emon; Md Munsur Alam; Irin Akter; Saima Akhter; Anjuman Ara Sneha; Md Irtiza; Marufa Afroj; Arifa Munni; Masruba Hossen Chowdhury; Summiya Hossain
Journal:  Futur J Pharm Sci       Date:  2021-06-15

Review 5.  Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.

Authors:  Colleen B Jonsson; Jennifer E Golden; Bernd Meibohm
Journal:  Curr Opin Virol       Date:  2021-06-29       Impact factor: 7.090

Review 6.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

7.  Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties.

Authors:  Daniel Scholes Rosenbloom; Ping Zhao; Vikram Sinha
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-08-27

Review 8.  Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Authors:  Melanie R Nicol; Abhay Joshi; Matthew L Rizk; Philip E Sabato; Radojka M Savic; David Wesche; Jenny H Zheng; Jack Cook
Journal:  Clin Pharmacol Ther       Date:  2020-09-01       Impact factor: 6.903

9.  Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.

Authors:  Karen Rowland Yeo; Mian Zhang; Xian Pan; Alice Ban Ke; Hannah M Jones; David Wesche; Lisa M Almond
Journal:  Clin Pharmacol Ther       Date:  2020-07-16       Impact factor: 6.903

10.  Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.

Authors:  Mohammad Tarek; Andrea Savarino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12       Impact factor: 2.569
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.